Supplements

curcumin improves ulcerative colitis remission

In plain terms: Does turmeric help ulcerative colitis?

Strong support Supplements

RefutedContestedStrong support

consensus score 0.82

Yes, as an add-on. Layered on top of standard therapy, curcumin improves remission rates in ulcerative colitis across several trials — one of its better-evidenced uses. It's an adjunct, not a replacement for your medication.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

9 support 0 contradict 0 tested null 2 mixed · 11 sources, 9 independent groups

What the evidence shows

One of curcumin's better gut claims: added on top of standard 5-ASA therapy, curcumin improves clinical response and remission in ulcerative colitis across several RCT meta-analyses. It's an adjunct to conventional treatment, not a standalone — and one prominent recent trial used a curcumin-indigo combination, so not all the benefit is curcumin alone.

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2012 · low Agrees with our grade

“Curcumin may be a safe and effective therapy for maintenance of remission in quiescent UC when given as adjunctive therapy along with mesalamine or sulfasalazine. However, further research in the form of a large scale methodologically rigorous randomized controlled trial is needed to confirm any possible benefit of curcumin in quiescent UC.”

Why we agree: we reached the same direction independently, from our own appraisal of 11 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (11)

Source	Grade	Stance	Quality	Finding
Mohseni S et al 2025 · study_type: meta-analysis	meta-analysis	supports	moderate	Systematic review/meta-analysis of 13 placebo-controlled RCTs of curcumin in IBD (mostly UC patients); curcumin significantly improved clinical remission and response in UC, though no superiority over placebo for CD clinical/endoscopic remi
Zheng 2020 · J Gastroenterol Hepatol	meta-analysis	supports	moderate	Meta-analysis of RCTs: adjuvant curcumin improved remission/response in ulcerative colitis vs standard therapy alone.
Xu R et al 2026 · study_type: meta-analysis	meta-analysis	mixed	moderate	Network meta-analysis, 24 RCTs/1,491 patients across 14 dietary supplements for UC; curcumin showed higher IBDQ (quality of life) scores vs conventional drugs/placebo (MD=25.80) but was NOT among the supplements showing significant advantag
Goulart 2020 · Expert Rev Gastroenterol Hepatol	meta-analysis	supports	moderate	SR+meta-analysis: curcumin improved clinical remission rates in ulcerative colitis as adjunct therapy.
Jiang H et al 2025 · study_type: animal	animal	supports	low	DSS-induced UC mouse model; curcumin+tryptophan combination outperformed either agent alone on weight loss, disease activity index, and colon length, with restored gut barrier function and microbiota.
Peng Z et al 2025 · study_type: meta-analysis	meta-analysis	supports	high	Updated systematic review/meta-analysis of 8 RCTs, 482 UC patients; adjunctive curcumin significantly improved clinical remission (RR=2.33, 95% CI 1.25-4.34) and clinical/endoscopic improvement, with a non-significant trend toward higher en
Zhao Y et al 2026 · study_type: RCT	RCT	supports	moderate	Prospective multicenter double-blind RCT, 159 moderate-to-severe UC patients (vedolizumab alone n=76 vs vedolizumab+curcumin n=83) over 26 weeks; combination group had significantly higher clinical remission rates at both 14 and 26 weeks pl
Gangwar T et al 2025 · study_type: observational	observational	supports	low	Narrative review of phytoconstituents (resveratrol, curcumin, quercetin, berberine, hesperidin) in UC; states experimental and clinical evidence suggests these compounds can reduce clinical manifestations, induce/sustain remission via anti-
Huang B et al 2025 · study_type: observational	meta-analysis	supports	moderate	Network meta-analysis of 34 RCTs (n=2,854) comparing mesalazine alone vs mesalazine + 8 TCM formulations including CurQD (curcumin+indigo naturalis); CurQD ranked highest (SUCRA 96.7%) for symptom improvement, direct comparison RR=2.67 (95%
Ben-Horin 2024 · Clin Gastroenterol Hepatol	RCT	mixed	moderate	Double-blind RCT: a curcumin-QingDai (indigo) combination induced response/remission in active UC — benefit not attributable to curcumin alone.
Yin 2022 · J Ethnopharmacol	meta-analysis	supports	moderate	SR+meta-analysis: adjuvant curcumin was efficacious and safe in ulcerative colitis.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.